



Rezatapopt (also known as PC14586) is a first-in-class, orally available, selective p53 reactivator


Rezatapopt is an investigational product and has not yet been approved by the US Food and Drug Administration (FDA) or any regulatory authority. The US FDA has granted Fast Track designation to rezatapopt for the treatment of cancer patients with locally advanced or metastatic solid tumors that have a TP53 Y220C mutation.




Normally, the **p53 tumor-suppressor protein** monitors your DNA for damage to prevent cancer growth

The mutated p53 Y220C protein can allow **tumor survival and growth**, and is found in 1% of all tumor types

The **TP53 Y220C mutation** is found in more than **30 tumor types**, including:



Rezatapopt selectively binds to a small pocket on the mutated p53 Y220C protein and causes a change in shape that **restores the tumor-suppressing activity** of non-mutated p53



The **TP53 Y220C mutation** results in a **mutated p53 Y220C protein**, causing changes to the shape of the protein and loss of binding to DNA



The mutated p53 Y220C protein can allow tumor survival and growth

Next-generation sequencing can be used to identify specific mutations in a tumor, including the **TP53 Y220C mutation**

The mutated p53 Y220C protein is a potential target for treatment. **Rezatapopt** is a pill under investigation as a selective **p53 reactivator**



People with solid tumors harboring the **TP53 Y220C** mutation are being recruited into the **PYNNACLE** study